Success Metrics

Clinical Success Rate

57.1%

Based on 4 completed trials

Completion Rate

57%(4/7)

Active Trials

5(36%)

Results Posted

75%(3 trials)

Terminated

3(21%)

Phase Distribution

Ph early_phase_1

14%

Ph not_applicable

Ph phase_2

21%

Ph phase_1

29%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Early Phase 1First-in-human

2(20.0%)

Phase 1Safety & dosage

4(40.0%)

Phase 2Efficacy & side effects

3(30.0%)

N/ANon-phased studies

1(10.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(4)

Terminated(3)

Other(2)

Detailed Status

Completed4

Recruiting3

Terminated3

Active, not recruiting2

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

57.1%

Most Advanced

Phase 2

Trials by Phase

Early Phase 12 (20.0%)

Phase 14 (40.0%)

Phase 23 (30.0%)

N/A1 (10.0%)

Trials by Status

completed429%

recruiting321%

active_not_recruiting214%

terminated321%

unknown214%

Recent Activity

5 active trials

Showing 5 of 14

recruitingphase_2

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

NCT07482072

View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials

NCT07829705Phase 2

Beta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CA

Recruiting

NCT06999434Phase 1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Recruiting

NCT05911178Not Applicable

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Active Not Recruiting

NCT04768101Early Phase 1

Quantitative Imaging of Brain Glymphatic Function in Humans

Active Not Recruiting

NCT07482072

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

Recruiting

NCT03981380

11C-PIB PET Study in MESA at Columbia University

Completed

NCT03958630Phase 1

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

Terminated

NCT03757910Early Phase 1

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Terminated

NCT06141356

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

Unknown

NCT04505735

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

Terminated

NCT01826110Phase 1

PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers

Completed

NCT03555292Phase 2

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Unknown

NCT02120664Phase 1

Florbetapir Calibration to the Centiloid Scale

Completed

NCT00855868Phase 2

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Completed

All 14 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 14